FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to infectious diseases, and can be used in treating HIV with cabotegravir and rilpivirine. Methods of the invention relate to the treatment of HIV-1 infection in a patient suffering virologic suppression, i.e. HIV-1 RNA less than 50 copies per ml, and which has no known or suspected resistance to cabotegravir or rilpivirine, and include regular intramuscular injections of cabotegravir or its salt and rilpivirine or its salt. Invention uses a combination of cabotegravir or its salt and rilpivirine or its salt.
EFFECT: use of inventions allows maintaining virological suppression when replacing the antiretroviral treatment regimen.
63 cl, 1 dwg, 19 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SCHEMES FOR TREATMENT OF HIV-INFECTIONS AND AIDS | 2018 |
|
RU2784810C2 |
| COMBINATION, ITS APPLICATION AND METHODS FOR TREATMENT USING SPECIFIED COMBINATION | 2018 |
|
RU2755710C2 |
| METHOD OF TREATING PATIENTS WITH HIV INFECTION | 2024 |
|
RU2840191C1 |
| LYOPHILIZED DRUG NANOSUSPENSIONS | 2012 |
|
RU2643062C2 |
| PHARMACEUTICAL NANOSUSPENSION FOR TREATMENT OF HIV INFECTION | 2017 |
|
RU2665383C1 |
| TWO-LAYER PHARMACEUTICAL DOSAGE FORM OF TABLETS | 2018 |
|
RU2803050C2 |
| TREATING AND PREVENTING HIV INFECTION | 2010 |
|
RU2569058C2 |
| COMPOSITION FOR REDUCTION OF CERAMIDE CONTENT | 1996 |
|
RU2203047C2 |
| N-ACETYLCYSTEINE-CONTAINING COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS AND TOXICITY OF DRUGS | 2002 |
|
RU2291689C2 |
| METHOD FOR DECREASING CERAMIDE CONTENT, SET COMPRISING ANTIRETROVIRAL MEDICINAL AGENT | 2001 |
|
RU2269340C2 |
